Interview: Konji Sebati – Chief Executive Officer, IPASA (Innovative…
The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients…
In April 2013, South African research-based pharmaceutical companies that previously belonged to either Innovative Medicines SA (IMSA) or the Pharmaceutical Industry Association of South Africa (PIASA), integrated to form a new association: the Innovative Pharmaceutical Industry Association South Africa (IPASA). This move created a single, unified voice for like-minded pharmaceutical organisations operating in South Africa. IPASA represents 25 leading pharmaceutical companies who are dedicated to exploring, developing and bringing innovative, quality medicines to the South African market. Only companies that conduct their own research and development qualify for membership. As the South African representative of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), IPASA has global reach and access to the latest developments in medicines and treatments around the world. Working groups drawn from our member companies collaborate closely with an aim to contribute to the ongoing development of the South African healthcare sector.
Contact
PO Box 2945, Randburg, 2125
404 Main Avenue, cnr Oxford Road
Ferndale, Randburg, 2125
Tel: (011) 781 3256
Fax: (011) 781 3328
Web: ipasa.co.za/
E-mail: xolile@ipasa.co.za
The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients…
David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the…
Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions,…
Medicines for Africa’s Lenias Hwenda highlights the vast gaps in COVID-19 vaccine access globally, especially in Africa where just six percent of the population has been vaccinated. Hwenda argues that…
Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase…
In a notable first, following successful pilot immunisation programmes in Ghana, Kenya and Malawi, the World Health Organization (WHO) has recommended that the RTS,S malaria vaccine be rolled out across…
A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials…
With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African…
The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s reception of USD 700 million in international financial aid, Adcock Ingram’s disappointing results as fewer…
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share…
As COVID-19 threatens to derail more than a decade’s worth of hard-won gains in the fight against malaria, Dr Benjamin Pretorius, managing director at ERADA Technology Alliance, warns that diversions…
The South African affiliate of Indian pharma firm Cipla will begin manufacturing and distribution of remdesivir, a Covid-19 drug, in South Africa this month. The company’s priority is ensuring access…
Below is a roundup of latest news from South Africa’s life sciences and healthcare industries, including a call to overhaul patent laws to allow better access to COVID-19 drugs, innovation…
See our Cookie Privacy Policy Here
